New drug duo targets Tough-to-Treat blood cancer
NCT ID NCT07447817
Summary
This study is testing whether a combination of two drugs, pacritinib and selinexor, can help control myelofibrosis in patients who have not yet tried a common type of treatment (JAK inhibitors) and who have low red blood cell and platelet counts. The main goals are to see if the treatment safely shrinks the enlarged spleen and improves patients' symptoms and blood counts. About 26 adults with intermediate or high-risk disease will participate.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for MYELOFIBROSIS are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Icahn School of Medicine at Mount Sinai
New York, New York, 10029, United States
Contact
-
The University of Kansas Cancer Center-Westwood
Westwood, Kansas, 66205, United States
Contact
-
Wake Forest Baptist Health Comprehensive Cancer Center
Winston-Salem, North Carolina, 27157, United States
Contact
Conditions
Explore the condition pages connected to this study.